261 related articles for article (PubMed ID: 32556898)
1. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
Tamiya M; Kunimasa K; Nishino K; Matsumoto S; Kawachi H; Kuno K; Inoue T; Kuhara H; Imamura F; Goto K; Kumagai T
Invest New Drugs; 2021 Feb; 39(1):232-236. PubMed ID: 32556898
[TBL] [Abstract][Full Text] [Related]
2. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
5. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
6. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
7. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
Fang YF; Liu PC
Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
[TBL] [Abstract][Full Text] [Related]
8. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
Liang SK; Ko JC; Yang JC; Shih JY
Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
[TBL] [Abstract][Full Text] [Related]
9.
Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
[TBL] [Abstract][Full Text] [Related]
10. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.
Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M
Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607
[TBL] [Abstract][Full Text] [Related]
11. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
Yang X; Huang C; Chen R; Zhao J
Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
[No Abstract] [Full Text] [Related]
12. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
Akamatsu H; Teraoka S; Morita S; Katakami N; Tachihara M; Daga H; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2019 Jul; 20(4):e492-e494. PubMed ID: 31085043
[TBL] [Abstract][Full Text] [Related]
13. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
15. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
[TBL] [Abstract][Full Text] [Related]
16. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
18. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
Zhang L; Sun L; Mu XY; Ji YX
Chin Med Sci J; 2019 Nov; 34(4):292-296. PubMed ID: 33906716
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.
Cai Y; Wang X; Guo Y; Sun C; Xu Y; Qiu S; Ma K
Medicine (Baltimore); 2019 Jan; 98(1):e13890. PubMed ID: 30608413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
